AUROBINDO PHARMA - stock earnings
AUROPHARMA.NS Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 25, 2024 BeforeMarket | - / - | - | - / 61.7 billion | - |
AUROPHARMA.NS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 9.4 billion INR | 72.7 billion INR |
| 2023Q3 | 7.6 billion INR | 71.5 billion INR |
| 2023Q2 | 5.7 billion INR | 67.9 billion INR |
| 2023Q1 | 5.1 billion INR | 63.8 billion INR |
| 2022Q4 | 4.9 billion INR | 63.9 billion INR |
| 2022Q3 | 4.1 billion INR | 56.7 billion INR |
| 2022Q2 | 5.2 billion INR | 61.8 billion INR |
| 2022Q1 | 5.7 billion INR | 61.8 billion INR |
| 2021Q4 | 6.0 billion INR | 59.9 billion INR |
| 2021Q3 | 7.0 billion INR | 58.9 billion INR |
| 2021Q2 | 7.7 billion INR | 56.9 billion INR |
| 2021Q1 | 8.0 billion INR | 59.9 billion INR |
| 2020Q4 | 29.5 billion INR | 63.5 billion INR |
| 2020Q3 | 8.1 billion INR | 63.8 billion INR |
| 2020Q2 | 7.8 billion INR | 58.4 billion INR |
| 2020Q1 | 8.5 billion INR | 60.6 billion INR |
| 2019Q4 | 7.1 billion INR | 58.0 billion INR |
| 2019Q3 | 6.4 billion INR | 56.0 billion INR |
| 2019Q2 | 6.4 billion INR | 54.4 billion INR |
| 2019Q1 | 5.9 billion INR | 49.5 billion INR |
| 2018Q4 | 7.1 billion INR | 52.7 billion INR |
| 2018Q3 | 6.1 billion INR | 47.5 billion INR |
| 2018Q2 | 4.6 billion INR | 42.5 billion INR |
| 2018Q1 | 5.3 billion INR | 40.5 billion INR |
| 2017Q4 | 6.0 billion INR | 43.4 billion INR |
| 2017Q3 | 7.8 billion INR | 44.4 billion INR |
| 2017Q2 | 5.2 billion INR | 36.8 billion INR |
| 2017Q1 | 5.3 billion INR | 36.4 billion INR |
| 2016Q4 | 5.8 billion INR | 39.1 billion INR |
| 2016Q3 | 6.1 billion INR | 37.8 billion INR |
| 2016Q2 | 5.8 billion INR | 37.3 billion INR |
| 2016Q1 | 5.5 billion INR | 37.5 billion INR |
| 2015Q4 | 5.3 billion INR | 35.0 billion INR |
| 2015Q3 | 4.5 billion INR | 33.3 billion INR |
| 2015Q2 | 4.3 billion INR | 33.2 billion INR |
| 2015Q1 | 4.0 billion INR | 30.8 billion INR |
| 2014Q4 | 3.8 billion INR | 31.7 billion INR |
| 2014Q3 | 3.7 billion INR | 28.8 billion INR |
| 2014Q2 | 4.2 billion INR | 29.1 billion INR |
| 2014Q1 | 5.0 billion INR | 22.7 billion INR |
| 2013Q4 | 4.2 billion INR | 21.4 billion INR |
| 2013Q3 | 2.3 billion INR | 19.1 billion INR |
| 2013Q2 | 186.0 million INR | 17.2 billion INR |
| 2013Q1 | 1.1 billion INR | 15.0 billion INR |
| 2012Q4 | 918.1 million INR | 15.7 billion INR |
| 2012Q3 | 2.2 billion INR | 15.0 billion INR |
| 2012Q2 | -1.3 billion INR | 12.1 billion INR |
| 2012Q1 | 1.1 billion INR | 11.2 billion INR |
| 2011Q4 | -285.4 million INR | 12.8 billion INR |
AUROPHARMA.NS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 19.3 billion INR | 246.2 billion INR |
| 2022 | 26.5 billion INR | 233.7 billion INR |
| 2021 | 53.3 billion INR | 245.6 billion INR |
| 2020 | 28.5 billion INR | 227.4 billion INR |
| 2019 | 28.3 billion INR | 192.3 billion INR |
| 2018 | 24.2 billion INR | 162.0 billion INR |
| 2017 | 23.0 billion INR | 146.6 billion INR |
| 2016 | 19.8 billion INR | 136.5 billion INR |
| 2015 | 15.8 billion INR | 120.4 billion INR |
| 2014 | 11.7 billion INR | 80.4 billion INR |
| 2013 | 2.9 billion INR | 57.8 billion INR |
| 2012 | -1.2 billion INR | 45.5 billion INR |
| 2011 | 5.6 billion INR | 43.8 billion INR |
| 2010 | 5.6 billion INR | 35.8 billion INR |
| 2009 | 1.0 billion INR | 30.8 billion INR |
| 2008 | 2.4 billion INR | 24.4 billion INR |
| 2007 | 2.0 billion INR | 21.2 billion INR |
| 2006 | 697.0 million INR | 15.9 billion INR |
| 2005 | 32.5 million INR | 13.2 billion INR |
| 2004 | 1.1 billion INR | 15.0 billion INR |
AUROPHARMA.NS
Price: ₹1,165.05
Dividend Yield: 0.00%
Forward Dividend Yield: 0.26%
Payout Ratio: 6.36%
Dividend Per Share: 3.00 INR
Earnings Per Share: 47.26 INR
P/E Ratio: 25.35
Exchange: NSI
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market Capitalization: 653.5 billion
Average Dividend Frequency: 2
Years Paying Dividends: 24
DGR3: 13.07%
DGR5: 24.07%
DGR10: 18.60%
DGR20: 30.00%